Literature DB >> 20659505

Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model.

Anurag Sharma1, Dinesh S Bangari, Manish Tandon, Harm Hogenesch, Suresh K Mittal.   

Abstract

Nonhuman adenovirus (Ad) vectors derived from bovine Ad serotype 3 (BAd3) or porcine Ad serotype 3 (PAd3) can circumvent pre-existing immunity against human Ad (HAd). We have previously reported differential transduction of human and nonhuman cells by these Ad vectors, and their distinct receptor usage and biodistribution. To compare the induction of innate immunity, vector toxicity and vector uptake by Kupffer cells (KCs) following intravenous administration of PAd3, BAd3, or HAd5 vectors in mice, we determined mRNA expression levels of proinflammatory chemokines and cytokines, and Toll-like receptors (TLRs) in the liver and spleen. Tissue toxicity of these vectors was assessed by comparing serum levels of liver-specific enzymes, histopathology and Kupffer cell (KC) depletion. Compared to the HAd5 vector, PAd3 and BAd3 vectors were more potent stimulators of innate immune responses as indicated by enhanced mRNA expression of TLRs and proinflammatory chemokines and cytokine genes. Histopathological changes in the liver were most pronounced in HAd5-inoculated mice while BAd3- or PAd3-inoculated mice revealed mild histologic changes that were confined to early time points. Inoculation with HAd5 or PAd3 vectors resulted in a significant (P<0.05) decline of the number of KCs in the liver. Together, these results extend our previous observations regarding distinct in vivo biology of nonhuman and human Ad vectors. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659505      PMCID: PMC2945211          DOI: 10.1016/j.virusres.2010.07.021

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  53 in total

1.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

2.  Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator.

Authors:  Marcelo Nociari; Oksana Ocheretina; John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 4.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

5.  Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo.

Authors:  Daniel M Appledorn; Sonika Patial; Aaron McBride; Sarah Godbehere; Nico Van Rooijen; Narayanan Parameswaran; Andrea Amalfitano
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

6.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.

Authors:  Anurag Sharma; Dinesh S Bangari; Manish Tandon; Aseem Pandey; Harm HogenEsch; Suresh K Mittal
Journal:  Virology       Date:  2009-02-10       Impact factor: 3.616

Review 8.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24

9.  Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; K Dee Carey; Milton Finegold; Philip Ng
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

Review 10.  Development of nonhuman adenoviruses as vaccine vectors.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

View more
  17 in total

Review 1.  Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.

Authors:  Tamsin Garrod; Branka Grubor-Bauk; Stanley Yu; Tessa Gargett; Eric J Gowans
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

2.  Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer.

Authors:  Manish Tandon; Anurag Sharma; Sai V Vemula; Dinesh S Bangari; Suresh K Mittal
Journal:  Virus Res       Date:  2011-09-29       Impact factor: 3.303

3.  Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.

Authors:  Jeffrey E Teigler; M Justin Iampietro; Dan H Barouch
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

4.  EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.

Authors:  Manish Tandon; Sai V Vemula; Anurag Sharma; Yadvinder S Ahi; Shalini Mittal; Dinesh S Bangari; Suresh K Mittal
Journal:  J Gene Med       Date:  2012-02       Impact factor: 4.565

5.  Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.

Authors:  Sergey A Kaliberov; Lyudmila N Kaliberova; Zhi Hong Lu; Meredith A Preuss; Justin A Barnes; Cecil R Stockard; William E Grizzle; Jeffrey M Arbeit; David T Curiel
Journal:  Virology       Date:  2013-10-15       Impact factor: 3.616

6.  Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors:  Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

7.  Loss of Hap1 selectively promotes striatal degeneration in Huntington disease mice.

Authors:  Qiong Liu; Siying Cheng; Huiming Yang; Louyin Zhu; Yongcheng Pan; Liang Jing; Beisha Tang; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

8.  A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism.

Authors:  M O Alberti; J S Deshane; D D Chaplin; L Pereboeva; D T Curiel; J C Roth
Journal:  Gene Ther       Date:  2012-11-22       Impact factor: 5.250

9.  Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.

Authors:  Aseem Pandey; Neetu Singh; Sai V Vemula; Laurent Couëtil; Jacqueline M Katz; Ruben Donis; Suryaprakash Sambhara; Suresh K Mittal
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

10.  A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model.

Authors:  Ami Patel; Suresh Tikoo; Gary Kobinger
Journal:  PLoS One       Date:  2010-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.